✦ LIBER ✦

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes

✍ Scribed by T. Ridge; T. Moretto; L. MacConell; R. Pencek; J. Han; C. Schulteis; L. Porter

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and Safety of Long-Acting Gluca

✍ Pinelli, N. R.; Hurren, K. M. 📂 Article 📅 2011 🏛 Harvey Whitney Books Company 🌐 English ⚖ 278 KB

Efficacy and Safety Profile of Exenatide

✍ Inagaki, Nobuya; Atsumi, Yoshihito; Oura, Tomonori; Saito, Hitoshi; Imaoka, Take 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 962 KB

Randomized, double-blind, placebo-contro

✍ Y. Seino; K. W. Min; E. Niemoeller; A. Takami; on behalf of the EFC10887 GETGOAL 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 602 KB